 |
|
Gene variant boosts risk of fatty liver disease, scientists discover
September 26, 2008Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation.
They also found that Hispanics are more likely to carry the gene variant responsible for higher liver-fat content than African-Americans and Caucasians.
The new findings, published online today in the journal Nature Genetics, provide a gene-based explanation for the results of a 2004 UT Southwestern-led study that determined that the propensity to develop nonalcoholic fatty liver disease differs among ethnic groups, with a higher percentage of Hispanics developing the disorder than African-Americans or Caucasians.
"A single variation in the PNPLA3 gene was strongly associated with hepatic fat content, even after adjusting for other factors, such as obesity, diabetes status and alcohol intake," said senior study author Dr. Helen Hobbs, director of the Eugene McDermott Center for Human Growth and Development and an investigator for the Howard Hughes Medical Institute at UT Southwestern.
"Sequence variations in this gene explain much of the increased propensity of Hispanics to accumulate excess liver fat," she said.
Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries, and its incidence is growing. Previous UT Southwestern research has shown that it may affect as many as one-third of adults in America.
"The gene variations we have identified might provide a way to predict who is most at risk for developing fatty liver disease and liver injury in response to environmental stresses such as obesity or infection," said Dr. Jonathan Cohen, professor of internal medicine in the McDermott Center and one of the authors of the study.
NAFLD results from the accumulation of triglycerides in the liver and is associated with metabolic disorders such as insulin resistance, obesity, diabetes and high cholesterol - many of the conditions that contribute to heart disease. It can also lead to liver inflammation, cirrhosis and liver cancer. Approximately 10 percent of liver transplants performed in the U.S. are for cirrhosis related to NAFLD, according to the researchers.
Treatments for NAFLD include weight loss, exercise, reducing alcohol intake and improved diabetes control.
"Knowing who is at increased risk of developing liver disease could aid physicians in encouraging their patients to make lifestyle changes or take other preventive measures to help mitigate their underlying genetic risk for the disorder," said Dr. Cohen, holder of the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.
The new findings come out of the Dallas Heart Study, an 8-year-old groundbreaking investigation of cardiovascular disease that involves a large multiethnic group of participants. The
$12 million study investigates the links between genetics, lifestyle and the risks for heart disease.
As part of the Dallas Heart Study, more than 3,500 individuals from Dallas County provided blood samples in 2000 for DNA isolation and other tests. Each participant also underwent multiple body scans with magnetic resonance imaging and computed tomography to examine the heart and other organs. Along with discovering new genetic ties to differences in blood levels of cholesterol and triglycerides, the researchers have used this information to identify new drug targets for the prevention and treatment of heart disease.
Data-gathering for the new study on fatty liver disease took advantage of a unique aspect of the Dallas Heart Study. Researchers with the study were the first to analyze hepatic fat in a large population using a technique called proton magnetic resonance spectroscopy - the most sensitive and quantitative noninvasive imaging technique available to measure the amount of fat in the liver. With this technique, they screened more than 2,100 individuals across multiple ethnicities. They then correlated that data with DNA tests from the same people and found the link to the PNPLA3 gene.
The next step in the research is to investigate how the various forms of the PNPLA3 gene affect lipid metabolism.
Other researchers from the McDermott Center involved with the study were lead author Dr. Stefano Romeo, a postdoctoral research fellow; Dr. Alexander Pertsemlidis, assistant professor; Dr. Chao Xing, assistant professor of clinical sciences; and Julia Kozlitina, a graduate student participating in a joint program between Southern Methodist University and UT Southwestern. Researchers from Perlegen Sciences, Lawrence Berkeley National Laboratory and the UT Health Science Center at Houston also were involved.
The research was funded by the Donald W. Reynolds Foundation, the National Institutes of Health and the Department of Energy.
The University of Texas Southwestern Medical Center at Dallas
"A single variation in the PNPLA3 gene was strongly associated with hepatic fat content, even after adjusting for other factors, such as obesity, diabetes status and alcohol intake," said senior study author Dr. Helen Hobbs, director of the Eugene McDermott Center for Human Growth and Development and an investigator for the Howard Hughes Medical Institute at UT Southwestern.
"Sequence variations in this gene explain much of the increased propensity of Hispanics to accumulate excess liver fat," she said.
Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries, and its incidence is growing. Previous UT Southwestern research has shown that it may affect as many as one-third of adults in America.
"The gene variations we have identified might provide a way to predict who is most at risk for developing fatty liver disease and liver injury in response to environmental stresses such as obesity or infection," said Dr. Jonathan Cohen, professor of internal medicine in the McDermott Center and one of the authors of the study.
NAFLD results from the accumulation of triglycerides in the liver and is associated with metabolic disorders such as insulin resistance, obesity, diabetes and high cholesterol - many of the conditions that contribute to heart disease. It can also lead to liver inflammation, cirrhosis and liver cancer. Approximately 10 percent of liver transplants performed in the U.S. are for cirrhosis related to NAFLD, according to the researchers.
Treatments for NAFLD include weight loss, exercise, reducing alcohol intake and improved diabetes control.
"Knowing who is at increased risk of developing liver disease could aid physicians in encouraging their patients to make lifestyle changes or take other preventive measures to help mitigate their underlying genetic risk for the disorder," said Dr. Cohen, holder of the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.
The new findings come out of the Dallas Heart Study, an 8-year-old groundbreaking investigation of cardiovascular disease that involves a large multiethnic group of participants. The
$12 million study investigates the links between genetics, lifestyle and the risks for heart disease.
As part of the Dallas Heart Study, more than 3,500 individuals from Dallas County provided blood samples in 2000 for DNA isolation and other tests. Each participant also underwent multiple body scans with magnetic resonance imaging and computed tomography to examine the heart and other organs. Along with discovering new genetic ties to differences in blood levels of cholesterol and triglycerides, the researchers have used this information to identify new drug targets for the prevention and treatment of heart disease.
Data-gathering for the new study on fatty liver disease took advantage of a unique aspect of the Dallas Heart Study. Researchers with the study were the first to analyze hepatic fat in a large population using a technique called proton magnetic resonance spectroscopy - the most sensitive and quantitative noninvasive imaging technique available to measure the amount of fat in the liver. With this technique, they screened more than 2,100 individuals across multiple ethnicities. They then correlated that data with DNA tests from the same people and found the link to the PNPLA3 gene.
The next step in the research is to investigate how the various forms of the PNPLA3 gene affect lipid metabolism.
Other researchers from the McDermott Center involved with the study were lead author Dr. Stefano Romeo, a postdoctoral research fellow; Dr. Alexander Pertsemlidis, assistant professor; Dr. Chao Xing, assistant professor of clinical sciences; and Julia Kozlitina, a graduate student participating in a joint program between Southern Methodist University and UT Southwestern. Researchers from Perlegen Sciences, Lawrence Berkeley National Laboratory and the UT Health Science Center at Houston also were involved.
The research was funded by the Donald W. Reynolds Foundation, the National Institutes of Health and the Department of Energy.
The University of Texas Southwestern Medical Center at Dallas
Liver Disease Current Events and Liver Disease News RSSAntibiotics: Single largest class of drugs causing liver injury
Antibiotics are the single largest class of agents that cause idiosyncratic drug-induced liver injury (DILI), reports a new study in Gastroenterology, an official journal of the American Gastroenterological Association (AGA) Institute.
Bariatric surgery may resolve liver disease
Obesity is a growing epidemic in the U.S. with a significant increase in prevalence from 15 percent to 32.9 percent from 1980 to 2004. Nonalcoholic fatty liver disease (NAFLD) is an emerging problem related to the obesity epidemic, becoming one of the most common causes of liver disease in the nation.
Melanin Production Discovered in Fat Tissue May Protect Some Individuals Against Chronic Diseases Associated with Obesity
A two-year study conducted by researchers at George Mason University, INOVA Fairfax Hospital and the National Cancer Institute may open the door to new therapies for combating chronic diseases associated with obesity, a condition that affected more than 33 percent of American adults in 2005-06 according to the Centers for Disease Control and Prevention.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease
A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time.
New MU Study Indicates that Exercise Prevents Fatty Liver Disease
It's easy to go to the gym on a regular basis right after a person buys the gym membership. It's also easy to skip the gym one day, then the next day and the day after that. A new University of Missouri study indicates that the negative effects of skipping exercise can occur in a short period.
If the diabetes has a direct carcinogenetic effect?
The association of DM2 with solid tumors, and particularly with HCC, has been long suspected and several studies have reported increased mortality rates for neoplastic diseases in patients with DM2.
Toxic Bile Damages the Liver
Researchers at the Heidelberg University Hospital have discovered a new genetic disease that can lead to severe liver damage. Because a protective component of the bile is missing, the liver cells are exposed to the toxic components of the bile, resulting in cirrhosis of liver, a transformation of liver cells into connective tissue with a gradual loss of liver function.
Are bone marrow mononuclear cells effective in reducing hepatic lesions?
Liver fibrosis occurs in the setting of chronic injury caused by different etiologies constituting a serious worldwide public health problem. In addition to schistosomiasis, hepatopathies due to alcohol, viral hepatitis, drugs, metabolic and autoimmune diseases, and congenital abnormalities are important causes of liver fibrosis.
The risk factors of idiopathic pulmonary fibrosis in HCV patients
Hepatitis C virus (HCV) is one of the more common causes of chronic liver disease in world with a variety of extrahepatic complications such as essential mixed cryoglobulinemia, membranoproliferative glomerulonep hritis, autoimmune thyroiditis, sialadenitis, and cardiomyopathy.
More Liver Disease Current Events and Liver Disease News Articles
 | Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death. In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition,... |
 | Hope For Healing Liver Disease In Your Dog: The Complete Story by Cyndi Smasal Liver disease is a serious and often fatal illness. The frustration and pain of a loved one can indeed be heart-wrenching when you are powerless to help, but what if that loved one is your dog? In 2001, Cyndi Smasal found herself in that position when her beloved dog, Norman, was diagnosed with liver disease. Not content with simply easing the pain of what should have been his final days,... |
 | Sleisenger and Fordtran's Gastrointestinal and Liver Disease e-dition: Pathophysiology, Diagnosis, Management (Gastrointestinal & Liver Disease (Sleisinger/Fordtran)) Access today's best guidance on the diagnosis and treatment of digestive disorders with the new edition of this best-selling reference! International experts provide evidence-based perspectives on all clinically relevant topics, explaining step by step how to apply the latest advances in practice. Succinct yet comprehensive discussions provide just the right amount of clinical detail. The... |
 | Pediatric Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management Here's everything you need to treat the full range of pediatric GI and liver diseases...in a convenient, concise single source. Drs Wyllie and Hyams - along with more than 80 experts in the field - bring you a clinically focused reference featuring a uniform chapter organization and a wealth of illustrations and diagrams to make guidance easy to both find and apply.Offers a bonus web site... |
 | Practical Management of Liver Diseases Practical Management of Liver Diseases is a practical reference for clinicians and trainees involved in the care of patients with liver diseases. It is designed to ensure that healthcare professionals are up to date on recent advances and can detect and treat these diseases rapidly and efficiently for maximum patient benefit. Each chapter is written by an international expert in the field of... |
 | HOPE FOR HEALING LIVER DISEASE IN YOUR DOG by Cyndi Smasal |
 | Schiff's Diseases of the Liver: Edited by Eugene R. Schiff, Michael F. Sorrell, Willis C. Maddrey (2 Vol. Set) by Eugene R Schiff, Michael F Sorrell, Willis C Maddrey The premier clinical reference in hepatology is now in its thoroughly revised, updated Ninth Edition. More than 100 eminent contributors provide complete, current, clinically focused information on liver diseases and discuss the diagnostic tests and medical and surgical treatment options available. The Ninth Edition includes new chapters on approach to the patient with liver disease, extrahepatic... |
 | Liver Disease in Children Completely revised new edition of the premier reference on pediatric liver disease. Liver Disease in Children, 3rd Edition provides authoritative coverage of every aspect of liver disease affecting infants, children, and adolescents. Chapters are written by international experts and address the unique pathophysiology, manifestations, and management of these disorders in the pediatric population. ... |
 | Handbook of Liver Disease by Lawrence S. Friedman, Emmet B. Keeffe Here's instant access to the symptoms, signs, differential diagnosis, and treatment for the full range of liver disorders. Written by an international 'who's who' of hepatology-and now in full color-this new 2nd Edition provides readers with top-notch, authoritative guidance they can count on!Discusses the hottest topics in the field, such as non-alcoholic steatohepatitis (NASH) and the latest... |
 | Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/ Management (2 Volume Set) by Mark Feldman, Lawrence S. Friedman, Marvin H. Sleisenger, Bruce F. Scharschmidt Univ. of Texas Southwestern, Dallas, TX. Brandon/Hill Medical List minimal-core and first-purchase selection (#189). Reference for students and practitioners. Each chapter includes a mini-outline with page citations, high-quality illustrations, and updated content. Previous edition: c1998. DNLM: Gastrointestinal... |
| © 2008 BrightSurf.com |